

Microbiome and Malignancy

Claudia S. Plottel^{1,*} and Martin J. Blaser^{1,2,3}

¹Department of Medicine, New York University Langone Medical Center

²Department of Microbiology, New York University Langone Medical Center

³Department of Biology

New York University, New York, NY 10016, USA

*Correspondence: claudia.plottel@nyumc.org

DOI 10.1016/j.chom.2011.10.003

Current knowledge is insufficient to explain why only a proportion of individuals exposed to environmental carcinogens or carrying a genetic predisposition to cancer develop disease. Clearly, other factors must be important, and one such element that has recently received attention is the human microbiome, the residential microbes including Bacteria, Archaea, Eukaryotes, and viruses that colonize humans. Here, we review principles and paradigms of microbiome-related malignancy, as illustrated by three specific microbial-host interactions. We review the effects of the microbiota on local and adjacent neoplasia, present the estrobolome model of distant effects, and discuss the complex interactions with a latent virus leading to malignancy. These are separate facets of a complex biology interfacing all the microbial species we harbor from birth onward toward early reproductive success and eventual senescence.

Introduction

Cancer, which manifests as the uncontrolled proliferation of host cells, is a leading cause of death in human societies worldwide. Disease and death result from local and distant spread of malignant cells, as well as from their metabolic and systemic effects. Although virtually all human tissues containing cells with replicating potential may be affected by cancer, there is host population specificity in the timing and tissues involved, in histology, and in natural history. While many genetic predispositions to increased cancer risk in general and to the development of specific malignancies have been identified, environmental effects dominate for virtually all of the major human cancers (Lichtenstein et al., 2000).

Significant exposures to environmental carcinogens, including toxic chemicals, ionizing radiation, and microbial pathogens, are extremely varied (Schottenfeld and Fraumeni, 2006). However, current knowledge is insufficient to explain why only a proportion of heavy smokers develop lung cancer, or who among those with hepatitis B infections will develop hepatomas. Clearly, other environmental factors must be important (Wynder and Gori, 1977), and one such element that has received attention more recently is the human microbiome.

Since their earliest origins (Ley et al., 2008a), animals have been colonized by residential micro-organisms, including bacteria, fungi, protozoa, and viruses, that are collectively described as the microbiome (Lederberg and McCray, 2001). With the development of new scientific tools, there has been increasing interest in the composition, function, stability, and host specificity of the microbiome, and the aggregate of its genes, the metagenome (Benson et al., 2010; Ley et al., 2006; Li et al., 2008). This review focuses on the relationships of the microbiome to human malignancy. We present general principles and explore three models of microbiome constituents affecting cancer risk and pathogenesis. The three paradigms we describe here illustrate different aspects of the emerging pathogenetic processes involving the microbiome.

General Principles

The Microbiome

Humans are colonized by residential microbes including Bacteria, Archaea, Eukaryotes, and viruses (Turnbaugh et al., 2007). The proportion of bacterial cells represented in the human body is estimated to be ~90%, and of all genes, >99%. Initial colonization occurs at the time of birth, and we progressively acquire a population of $\sim 10^{14}$ bacterial cells at equilibrium, which essentially remain for life, and this process is recapitulated in every human lifetime. A human virome consisting of persistent colonizing viruses also exists, but is far less explored. Preliminary examination of the fecal virome has shown numerous bacteriophages, but with no obvious relationship to neoplasia (Reyes et al., 2010).

Each anatomical niche possesses its own mixture of microbial populations. Although generally conserved at higher taxonomic levels and in functional properties (Arumugam et al., 2011) between all humans, interindividual microbiota variation at lower levels (genus, species, and strain) is enormous (Qin et al., 2010). The microbiome composition appears to evolve over the human life span, but the exact magnitude of such changes is unknown. The individual organisms and cells in the microbiome both compete and cooperate with one another (Blaser and Kirschner, 2007), and the metagenome has both functional and genetic plasticity (Arumugam et al., 2011; Muegge et al., 2011).

Interactions with Hosts

We do not carry our microbial load passively. There is increasing evidence for a rich, complex, dynamic, and individual-specific microbial interaction with hosts. Interactions involve microbial signaling of host cells that affect metabolic, neurological, inflammatory, immunologic, and host-defense functions, among others (Barton et al., 2007; Dethlefsen et al., 2007; Ley et al., 2008b; Muegge et al., 2011). The nature of host responses also shapes microbiome populations and metabolism (Vijay-Kumar et al., 2010). Indeed, a long-term, well-choreographed Nash equilibrium may model host-microbial coevolution (Blaser and Kirschner, 2007). The range of equilibrium arrangements is




Figure 1. Equilibrium between Coevolved Microbes and Host Cells

(A) Single organism equilibrium. In this model, there is a counter-regulatory (negative feedback) interaction involving metabolic and physical signals between microbe and host.

(B) Multiple organisms in equilibrium. In this much more complex system, organisms may have individual equilibrium relationships (e.g., i and ii) with host cells as in (A). However, the interaction between these two microbes (iii) will affect their individual interactions. Similarly, another microbe (iv) might interact exclusively with an organism (i), but not with the host, with the extent of the interaction affecting the equilibrium relationships. An alternative is that an interactive microbe (i) can interact with a second

microbe (v) that directly signals the host, but does not receive direct host signals back. Finally, the host might have a specific interaction with another microbe (shown as vi), which can have a unidirectional interaction with microbes (e.g., with organism i) but not directly with the host.

broad; simplified formulations are shown in Figure 1. Host interactions with the microbiome are both local, e.g., in the gastrointestinal tract lumen, or distant, involving hormonal intermediates, microbial metabolites, and immunologic messengers.

Human cancers must be considered against the background of host-microbiome interactions. In general, cancers are log linear with host age (Nordling, 1953). Three questions are relevant to this review: How are cancers initiated? Why do some but not all tumors progress? What determines susceptibility to treatment? In summary, there is a theoretical basis for the microbiome to participate in each of these phenomena (Figure 2). For example, microbiome-induced recruitment of lamina propria innate and adaptive immune effectors induces epithelial cell proliferation (Israel et al., 2001), and cell proliferation per se is pro-oncogenic (Ames and Gold, 1990). Microbial adjuvancy or suppression affects immune surveillance (Gaboriau-Routhiau et al., 2009; Ivanov et al., 2009), which limits tumor progression. Differing drug metabolism affects susceptibility to chemotherapy (Wallace et al., 2010).

We are living at a time of great ecological change: global warming at the macro level and “disappearing microbiota” at the micro level (Blaser and Falkow, 2009). Thus, long-established human-microbial ecological relationships and their contribution to

cancer risk are changing. For example, in developed countries, the incidence of gastric cancer is falling, whereas esophageal adenocarcinoma is rising (see below). Nevertheless, several different types of cancer development can be considered (Figure 3) at the crossroads of our ancient and our “postmodern” microbiota. Of the microbe-induced human malignancies, Class A is defined as involving immunologic tissues, Class B requires direct microbial interactions with parenchymal cells, and Class C involves distant effects from local interactions. Several examples (Table 1) may provide a model for not-yet-recognized relationships between microbiome and particular cancers (Blaser, 2008). We illustrate general types of relationships between different constituents of the human microbiome and several human cancers through the following paradigms.

Paradigm 1: Active Inflammation Promoting Cancer in a Luminal Organ

H. pylori are microaerophilic, highly motile, curved gram-negative bacilli that colonize the human stomach (Atherton and Blaser, 2009). Considerable evidence reveals that *H. pylori* is ancestral in humans, colonizing our ancestors before the major out-of-Africa migration 58,000 years ago (Linz et al., 2007). Acquired in early childhood and carried for nearly all of




Figure 2. Mechanisms by which the Microbiome Can Enhance Malignant Transformation and Cancer Spread

Cancer involves the transformation of physiologically responsive cells into autonomously replicating tumors that have the capacity to invade local tissues or spread widely. Multiple host processes (indicated on the left) govern the success of neoplastic cells to cause cancer. However, the interaction of the microbiome with the host (right) yields effects that can enhance or suppress tumorigenesis. Microbiome-induced inflammation affects the initiation (“EARLY”) of cancers. Medium-term interactions affect multiple facets that influence whether or not tumors progress and, if so, in which ways. Finally, “LATE” interactions affect the susceptibility of the tumor to therapies.




Figure 3. Classification of Microbiome-Associated Human Malignancies

Three types of relationships can be envisaged between the microbiome and mechanisms that give rise of cancers. In Class A, the primary interactions involve immunocytes; in Class B, local parenchymal cells; and in Class C, the local interactions produce distant effects. Specific examples of all three classes are indicated in Table 1. Adapted from Blaser (2008) with permission.

the life span, *H. pylori* was ubiquitous in all human populations in which it was studied (Bardhan, 1997). Also, examination of gastric 16S rRNA genes indicates that *H. pylori* dominates the gastric microbiota (Andersson et al., 2008; Bik et al., 2006). Thus, *H. pylori* has been the ancient, dominant, and highly interactive member of the human gastric microbiota. Nevertheless, *H. pylori* prevalence has steadily decreased over the course of the 20th century (Chen and Blaser, 2008; Roosendaal et al., 1997); this is both a major and surprising shift in human microecology.

As such, we can now measure the consequences of carrying *H. pylori* or not. As discussed below, the presence or absence of the organism can lead to very different gastric physiologies, and each of the three classes of microbe-induced malignancies outlined in Figure 3 can be attributed to the presence or absence

of *H. pylori*. Substantial epidemiologic, histologic, and experimental animal studies implicate *H. pylori* in the causation of gastric adenocarcinoma (Peek and Blaser, 2002), the second leading cause of cancer death worldwide (Class B relationship). In addition, *H. pylori* is strongly associated with gastric MALT-lymphomas (Parsonnet et al., 1994) (Class A relationship). Conversely, *H. pylori* has an inverse association with esophageal (gastro-esophageal junction) adenocarcinoma, consistent with a protective effect (Islami and Kamangar, 2008) (Class C relationship).

Gastric Cancer

Via secreted substances, physical attachment, and the injection by a type IV secretion system (TFSS) of its own constituents, *H. pylori* are highly interactive with host cells (Odenbreit et al., 2000), consistent with the Class B model (Figure 3). A major injected constituent is the ~128 kDa CagA protein, which contains several tyrosine phosphorylation (EPIYA) domains that are recognized by host cell kinases, which convert CagA into p-CagA (Backert and Selbach, 2008). As an indication of *H. pylori* complexity, the EPIYA-rich encoding region contains

Table 1. Examples of Microbe-Induced Human Malignancies by Class

Microbe(s)	Examples of Malignancies by Class		
	A	B	C
EBV ^a	Lymphomas	Nasopharyngeal carcinoma	
HTLV-1	ATL		
HHV-8		Kaposi's sarcoma	
HIV	Lymphomas	Kaposi's sarcoma	
Hepatitis B		Hepatocellular carcinoma	
Hepatitis C	Lymphomas	Hepatocellular carcinoma	
<i>H. pylori</i> ^a	MALT gastric lymphoma	Gastric adenocarcinoma	[Esophageal adenocarcinoma] ^b
HPV		Anogenital carcinomas, oropharyngeal carcinoma	
Schistosomal species		Bladder cancer	
Liver flukes		Cholangiocarcinoma	
Hypothesized scenarios: microbiome			{ [Breast and endometrial adenocarcinomas] [Testicular and prostate adenocarcinomas]
ΔMicrobiome ^c } Microbiome }		Colon adenocarcinoma	

Abbreviations: ATL, adult T cell leukemia/lymphoma; HHV-8, human herpesvirus 8; HTLV-1, human T cell lymphotropic virus type 1; MALT, mucosa-associated lymphoid tissue. Adapted from Blaser (2008) with permission.

^a Represents microbes that are constituents of the ancestral human microbiome.

^b Brackets indicate that the presence of a specific microbe (e.g. *H. pylori*) or as yet unidentified member(s) of the microbiome may either inhibit or promote the development of the bracketed malignancy.

^c In addition to metabolic activities of usual microbial constituents, changes (Δ) in the microbiome also may be involved in inducing some cancers.




Figure 4. Multi-Decade Development of Gastric Adenocarcinoma Initiated by *H. pylori*: Ecologic Model

(A–D) The equilibrium relationship of *H. pylori* and its host involves recruitment of a population of immune and inflammatory cells in the gastric lamina propria (A). Over time (decades), the conjunction of the organism and its host response results in continued injury to the epithelium with progressive loss of normal architecture and function (B). This leads to the development of atrophic gastritis (C), with permanently altered architecture, and a reduction in acid secretory function. With hypochlorhydria, the gastric niche now is dominated by competing microbiome members that have pathogenic properties leading to further inflammation and tissue injury (D). Over this decades-long (essentially lifelong) progression, *H. pylori* bacterial populations gradually decline. In the final stage, the *H. pylori*-induced atrophic gastritis lowers gastric acidity, which then is a reduced barrier to the intrusion of adventitious pathogenic oropharyngeal and intestinal bacteria.

many DNA repeats, permitting the expansion or diminution of EPIYA site number. Strains with C- or D-type EPIYAs signal host epithelial cells via the Src/Shp-2/MAPK pathway, whereas EPIYA lacking proteins signal through gp130/JAK/STAT3 (Lee et al., 2010). Since these are cross-inhibitory pathways, the population biology of *H. pylori* within a particular locale determines, with very fine tuning, the nature of host responses, enabling persistence, but also leading to tissue responses and injury. Individuals carrying *H. pylori* strains that possess CagA are at increased risk for the development of precursor lesions for gastric cancer (i.e., atrophic gastritis and intestinal metaplasia) and therefore the cancer itself. Multiple signaling pathways may be involved, since particular alleles of *H. pylori* genes are associated with increased risk of cancer development (Batista et al., 2011). Particular host polymorphisms that relate to innate immunity (e.g., affecting IL-1, IL-1RA, and TNF- α expression) enhance the risk of gastric cancer associated with *H. pylori* positivity (El-Omar et al., 2001, 2003; Figueiredo et al., 2002). *H. pylori*-induced gastric inflammation recruits stem cells from the bone marrow, which may also participate in tumorigenesis (Houghton et al., 2004). The traditional model of gastric carcinogenesis focuses on host, strain, or interaction differences in explaining *H. pylori*-induced gastric adenocarcinoma (Peek and Blaser, 2002). An alternative model is shown in Figure 4 in which the *H. pylori*-host interaction causes progressive degradation of the gastric niche over decades, *H. pylori* is essentially lost (Karnes et al., 1991), and the changes lead to the success of new competing microbiome populations that are cancer promoting.

Gastric Lymphoma

The presence of *H. pylori* is strongly associated with primary gastric lymphoma (Parsonnet et al., 1994; Wotherspoon et al., 1993). The presence of *H. pylori* is important in the proliferation of the tumors, since when *H. pylori* is eliminated, they often regress (Yamamoto et al., 2008; Zullo et al., 2010). The tumors are clonal, but a spectrum encompassing benign polyclonal lymphoid expansion, emergence of a dominant clone, and malignant transformation of the clone can be observed (Thiede et al., 2001). This scenario is consistent with the Class A model for microbiome-mediated hematopoietic and lymphoid malignancies as outlined in Figure 3.

Esophageal Adenocarcinoma

The incidence of GE junction adenocarcinomas (namely esophageal adenocarcinoma [EAC] and gastric cardia adenocarcinoma) is rapidly rising in Western countries (Devesa et al., 1998) just as *H. pylori* is disappearing (Chen and Blaser, 2008; Roosendaal et al., 1997). The development of these cancers (and those on the gastric cardia side of the GE junction) follows gastro-esophageal reflux disease (GERD) and its metaplastic sequela (Barrett's esophagus). The presence of *H. pylori*, especially cagA+ strains, is inversely associated with all three lesions (Peek and Blaser, 2002). These findings have been confirmed (Islami and Kamangar, 2008) and are consistent with the hypothesis that a change in the gastric microbiome resulting from the absence of *H. pylori* is contributing to this epidemic of GE junction adenocarcinomas. This is biologically plausible based on emerging trends and on the knowledge that loss of these highly interactive (especially cagA+) organisms changes gastric physiology, affecting acid secretion (Moss et al., 1992), hormone interactions (Francois et al., 2008, 2011), and T cell populations (Robinson et al., 2008). Further, the loss of *H. pylori* is associated with changes in the composition of the gastric microbiome involving many other microbial taxa (Maldonado-Contreras et al., 2011). That change in the microbiome in one location (gastric) may affect cancer risk in an adjacent, but separate, compartment (distal esophagus) suggests an important paradigm for other cancers: the causal agents need not be residents of the affected tissues (Figure 3, Class C). Nevertheless, there is an esophageal microbiota (Pei et al., 2004) that is clearly perturbed in pre-malignant lesions of the esophagus (Yang et al., 2009). Whether this is cause or effect is uncertain at present but is a promising area for exploration.

Paradigm 2: Metabolic Effects of Residential Organisms Leading to Distant Malignancies

The Human Estrobolome

We postulate that an important contribution of the human gut microbiota to host physiology is a functional estrobolome, the aggregate of enteric bacterial genes whose products are capable of metabolizing estrogens. Especially important are bacterial species possessing β -glucuronidases and β -glucuronides, enzymes involved in estrogen deconjugation and conjugation




Figure 5. The Estrobolome and Its Switch

Estrogens are steroid hormones derived from the stepwise reduction of C21 cholesterol. The ovaries are the only organs capable of full C21 (cholesterol) → C18 (estrogen) synthesis; at all other sites of estrogen synthesis (e.g., adrenals, adipose tissue), the availability of C19 androgens as substrates and aromatase are limiting factors. Estrogens circulate in the bloodstream free or protein bound and are conjugated or unconjugated molecules that may enter target tissues or be eliminated by the kidneys. Circulating estrogens undergo Phase I hepatic metabolism. In the liver, estrogens and their resultant estrogen metabolites (EMs) then may be conjugated through methylation, glucuronidation, or sulfonation reactions. Conjugated estrogens are subject to biliary excretion. The estrobolome, the aggregate of enteric bacterial genes whose products are capable of metabolizing estrogens, acts on conjugated estrogens and estrogen metabolites with downstream physiologic effects. An estrobolome enriched in genes encoding enzymes favoring deconjugation promotes reabsorption of free estrogens that contribute to the host's total estrogen burden. Suppression of deconjugation, which may follow antibiotic exposure, leads to increased estrogen excretion (Martin et al., 1975). Estrobolomes varying in functional activity lead to different host-estrogen equilibria via enterohepatic circulation of varied proportions of conjugated to unconjugated estrogens. The composition of the estrobolome can be modulated by host-specific and/or environmental drivers (e.g., antibiotics) exerting selective pressure on its

parental bacterial populations. Shown here for illustration is the ratio of 2-OH/16-OH hydroxylated EMs, which may serve as urinary or serum markers of risk for certain estrogen related cancers (Bradlow et al., 1995; Gupta et al., 1998; Kabat et al., 1997; Meilahn et al., 1998; Muti et al., 2000)

(Cole et al., 1985; Dabek et al., 2008; Gabelle et al., 1985; Gloux et al., 2011; McBain and Macfarlane, 1998). The estrobolome is predicted to impact endogenous estrogen metabolism by modulating the enterohepatic circulation of estrogens, thus affecting circulating and excreted estrogen levels (Figure 5). A woman's lifetime burden of estrogen exposure may reflect in part the metabolic functioning of her estrobolome. An estrobolome enriched in gene products promoting estrogen metabolite deconjugation reactions may result in greater reabsorption of free estrogens. Estrobolome variation in levels of functional deconjugative ability may thus influence development of estrogen-driven neoplasia (Figure 3, Class C).

Estrogens and Estrogen-Driven Cancer

Estrogens, steroid hormones derived from the progressive reduction of C21 cholesterol, may act locally (intracrine function) or circulate to exert effects on target organs (endocrine function). The three major forms of endogenous estrogen, estradiol (E₂, dominant during reproductive years), estrone (E₁, dominant after menopause), and estriol (E₃, dominant during pregnancy), are four-ring C18 molecules. Estrogens appear in circulation as free or protein-bound entities and in both conjugated and unconjugated states. Estrogen exposure begins prenatally and is life-long. The multiple beneficial effects (cardiovascular, metabolic, bone, fertility, cognition) contrast with roles in estrogen-driven cancers. Women with the highest circulating estrogen levels are at increased risk for developing postmenopausal endometrial (Lukanova et al., 2004) and breast cancers (Hankinson et al., 1998; Kaaks et al., 2005; Key et al., 2002; Lukanova et al., 2004; Toniolo et al., 1995; Woolcott et al., 2010). Estrogen metabolism varies between women, with the full physiologic repertoire of its metabolites being unknown. Estrogens and estrogen-like molecules classically exert their cellular effects

by binding to and activating estrogen receptors, although other receptor-independent mechanisms do exist.

Healthy and Cancerous Cells Express Receptors for Estrogen

The two recognized estrogen receptors (ER α , ER β) are homologous ligand-modulated transcription factors. Both are present in many healthy tissues (including breast, ovary, testis, prostate, bone, brain, and vascular system) and in certain cancers of the breast, endometrium, prostate, bone, and lung (Kuiper et al., 1996). Ligands other than E₂, E₁, and E₃ can bind with varying affinities to both ER α and ER β (Kuiper et al., 1998) with activation increasing or repressing host cell transcription with consequent biologic activity (Jeyakumar et al., 2011). The centrality of estrogen to malignancy is reflected in therapeutic interventions that target estrogen receptor signaling, including the selective estrogen receptor antagonists (SERMs), widely used to treat ER(α)-receptor-expressing breast cancer.

Hepatic Estrogen Metabolism and the Enterohepatic Circulation of Estrogens

Both E₁ and E₂ undergo Phase I oxidative hepatic metabolism, leading to the formation of catechol estrogens (e.g., 2-OH, 4-OH, and 16-OH estrogens) (Yager et al., 2009) that then are conjugated or transformed to semiquinones, which have been implicated in oncogenesis (Cavaliere et al., 2006). The ratio of circulating and urinary 2-OH to 16-OH estrogen pathway metabolites may be a marker of breast and endometrial cancer risk (Bradlow et al., 1995; Gupta et al., 1998; Kabat et al., 1997; Meilahn et al., 1998; Muti et al., 2000). Phase II hepatic conjugation reactions include methylation via catechol-O-methyltransferase, glucuronidation via uridine 5'-diphospho-glucuronosyltransferase, and sulfonation via sulphotransferase (Raftogianis et al., 2000). Some methylated estrogens, such as 2-methoxyestradiol,

exhibit proapoptotic, antiangiogenic, and antiproliferative activities (Lakhani et al., 2003) and are currently being studied as anticancer agents. Conjugated estrogens are not important ligands for the estrogen receptors (Raftogianis et al., 2000) and are subject to biliary excretion (Adlercreutz and Martin, 1980; Sandberg and Slaunwhite, 1957). Most importantly, there is an enterohepatic circulation of estrogens (Figure 5) with repeated recirculation circuits (Adlercreutz, 1962; Sandberg and Slaunwhite, 1957). Recent refinements in analytic methodologies now permit accurate measurements of conjugated and unconjugated estrogens and estrogen metabolites in serum and urine (Ziegler et al., 2010) and should stimulate investigations of estrogen metabolism in malignancies.

Estrogen Metabolism Requires a Functional Estrobolome

Gut microbial functions driving estrogen metabolism and contributing to the proportions of recirculated and excreted estrogens and estrogen metabolites have long been considered (Adlercreutz and Järvenpää, 1982; Eriksson, 1970). Reduction in populations of specific gut bacteria in humans, as occurs with exposure to antibiotics, causes increased fecal excretion of conjugated estrogens and decreases in urinary estrogens (Martin et al., 1975), highlighting the modulatory role of the gut microbiome's deconjugating machinery (Adlercreutz and Järvenpää, 1982; Adlercreutz et al., 1978, 1979; Martin et al., 1975). Human fecal extracts metabolize estrogens *ex vivo*, as would be expected of the estrobolome. The reactions include reduction, oxidation, and the generation of E₂ from E₁ as well as from estradiol 3-glucuronide, E₁ from E₂ and from estrone 3-sulfate, and E₃ from 16 α -hydroxyestrone (Lombardi et al., 1978). Similarly, *in vitro* incubation of E₁, E₂, and 16 α -hydroxyestrone with human feces leads to the interconversion of E₁ and E₂ and the reduction of 16 α -hydroxyestrone to E₃, 16-oxoestradiol to 16-epiestriol, and 15 α -hydroxyestrone to 15 α -hydroxyestradiol (Järvenpää et al., 1980). Finally, germ-free mice provide additional evidence for the centrality of host-microbe interactions in estrogen metabolism (Shimizu et al., 1998).

Interventions that Target the Estrobolome Affect Estrogens

Bacterial composition of the human estrobolome likely reflects host factors, such as delivery mode at birth, as well as lifetime environmental influences, including antibiotic use and dietary composition. Vegetarians have increased fecal excretion of conjugated estrogens (Goldin et al., 1982; Gorbach and Goldin, 1987), and dietary manipulations affect overall gut microbiome composition and function (Turnbaugh et al., 2009; Faith et al., 2011; Muegge et al., 2011). Such pressures exerted over time on the bacterial communities that constitute the estrobolome may lead to emergence of functionally distinct patterns, analogous to the broader categorization of the gut phylogenetic enterotypes (Arumugam et al., 2011). The confluence of both genetic and environmental modulators may shape estrobolome functionality that affects cancer risk (Figure 5); as such, estrobolome analysis could be harnessed to reduce emergence of estrogen-driven malignancies, such as Type I (endometrioid) endometrial cancer, estrogen receptor-positive breast cancer, and some ovarian cancers. Interventions that modify the bacterial constituents of the estrobolome also could modulate functional activity. Manipulations that specifically target species with

β -glucuronidase and β -glucuronide activities could aid in reducing estrogen-related cancer risk. Changing bacterial populations to diminish hydroxylation and reductive functions can be accomplished with antimicrobial agents, prebiotics, or probiotics. If such interventions proved successful, estrobolome status might inform future risk of malignancy, and measures could target restoration and maintenance of a "healthy" estrobolome for that host.

Paradigm 3: Abrogation of Clinical Latency Leading to Malignant Outcomes

Epstein-Barr Virus

Epstein-Barr virus (EBV) is an ancient (Lacoste et al., 2010; McGeoch et al., 1995), ubiquitous, and persistent virus that obligately infects humans, leading to lifelong latency. By adulthood, nearly all humans have acquired EBV (Henle et al., 1969). As such, EBV should be considered part of the human virome, and it is with this premise that we discuss EBV and associated malignancies in this review.

EBV is a 172 kb, double-stranded DNA virus of the γ -herpesvirus subfamily of *Lymphocryptovirus*, present as a characteristic (Penkert and Kalejta, 2011) circular episome within the human memory B-lymphocyte nucleus (Niederman et al., 1970). EBV is associated with relatively low short-term cost and even possible benefit to the host (Barton et al., 2007), but harbors long-term malignant potential. The emergence of an EBV-associated cancer, often decades after EBV acquisition, reflects complex interactions between the virus and its host that culminate in the loss of latency and highlight how a nearly universal member of our commensal microbiota contributes to malignancy. In hosts who develop Burkitt's lymphoma, posttransplantation lymphoproliferative disorders (PTLD), or nasopharyngeal carcinoma (NC), EBV has a biphasic life cycle. However, most EBV-positive individuals do not develop EBV-associated cancers, but instead just harbor latent virus. EBV's presence is thus necessary but not sufficient for the emergence of an EBV-associated malignancy.

Interactions of Epstein-Barr Virus with Its Human Host

EBV is transmitted between humans through saliva. Children become susceptible to EBV transmission after maternal antibody protection wanes; infection is either asymptomatic or may lead to nonspecific symptoms. EBV acquisition in adolescence or in young adulthood, as seen in Western societies, results in illness termed infectious mononucleosis (IM) in about half of the infected individuals. The intensity of the host's T cell responses to primary EBV is responsible for this acute illness (Callan et al., 1996).

After the initial replicative lytic phase, EBV undergoes a shift to one of a series of tightly regulated latency states, each characterized by transcriptional repression to evade immune surveillance (Figure 6). Differential regulation of promoter utilization underlies EBV latency gene expression, possibly involving chromatin insulator protein (Tempera et al., 2011). Compared to the >80 genes expressed in the lytic cycle, in a Latency III program EBV principally expresses six nuclear antigens (EBNAs) and all three integral latent membrane proteins (LMPs), whereas in Latency II only EBNA1 and LMP1 and 2 are expressed, and in Latency I only EBNA1 is expressed (Figure 6). EBNA1 is crucial for EBV episome replication and maintenance, and Latency I represents




Figure 6. Schematic of EBV-Host Interactions

(A) EBV (teal virions with black tip) is acquired orally and targets B cells (lavender nucleated circles) and permissive epithelial cells of the oral pharynx (green). The major EBV envelope glycoproteins gp350 and gp220 (black tip) interact with complement receptor CD21 (brown) on the surface of naive resting B lymphocytes, leading to viral binding. Additional EBV B cell interactions involving fusion proteins and HLA class II molecules (not shown) lead to virus-cell fusion and EBV internalization. EBV bound to the B cell surface likely allows for its transfer to oropharyngeal epithelial cells. The initial lytic viral reproductive phase may be asymptomatic (usually) or may manifest clinical symptoms and is termed infectious mononucleosis (IM). During the lytic phase, virus is shed via the saliva and can infect naive hosts.

(B) After the initial lytic phase, EBV evades host immunosurveillance to achieve persistence through “translational latency,” the tightly regulated selective expression of viral latent proteins and of noncoding RNAs. The former include six Epstein-Barr virus nuclear antigens (EBNAs) (1, 2, 3A, 3B, 3C, and LP) and three integral latent membrane proteins (LMPs) (1, 2A, and 2B). The latter include EBERs (1 and 2), small noncoding RNAs abundantly expressed in latently infected EBV cells, as well as multiple microRNAs that contribute to EBV-associated cellular transformation. EBV miRNAs are encoded by two transcripts (in the BART and BHRF1 loci). Three distinct “transitional” EBV latency programs (Latency I, II, and III) are characterized by specific gene expression profiles that allow for establishing latency and enhancing cell survival

and proliferation. After the initial lytic phase, EBV replicates as an episome in tandem with the host cell genome. EBV employs host cell-driven DNA genomic methylation and modulation of NF κ B activity and Notch signaling pathway manipulations (not shown) to establish true latency (Latency 0) in resting memory B cells (purple circles), with highly restricted EBV gene expression. Nonpathogenic and invisible to the host immune system, Latency 0 EBV persistently populates memory B lymphocytes. In the course of the latently infected hosts’ life, episodic disruptions of latency occur (depicted as “STRESS” and yellow bolt), resulting in EBV replication and viral shedding with potential spread to other hosts. Latent EBV also can contribute to several cancers (dashed line), including lymphomas such as Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC). Exogenous immunosuppression may result in posttransplantation lymphoproliferative disorders (PTLD). The emergence of malignancy appears to require interactions of cofactors, for example *P. falciparum* in BL, and individual host characteristics, including HLA type in NPC.

the most restrictive form of latency in dividing cells. A state of “Latency 0” in which there is no viral antigen expression is postulated to occur in vivo, consistent with the lifelong persistence of the EBV genome in memory B cells in healthy hosts (Babcock et al., 1998; Miyashita et al., 1995). Even in latency, EBV is capable of regulating B cell protein expression and proliferation, and the viral genome can replicate as an episome, in tandem with host cell division.

EBV Manipulates Host Innate Immune Signaling Pathways

EBV exploits fundamental host innate signaling pathways, including NF κ B, TNF- α , and Notch receptor pathways, throughout its life cycle. It does so to its advantage, beginning when viral envelope glycoprotein (gp350/220) binds to host B cell surface CD21 and TLR2, leading to persistent NF κ B classical pathway activation (Gaudreault et al., 2007). Later, EBV achieves immortalization via activation of both the alternative and classical NF κ B pathways (Kung and Raab-Traub, 2010; Mosialos et al., 1995; Song and Kang, 2010). EBV is able to convert host B lymphocytes into lymphoblastoid cell lines by expressing EBV nuclear and membrane proteins, EBNAs, and LMPs (in Latency III) that regulate transcription through the Notch and TNF- α receptor pathways (Cahir-McFarland et al., 2004). EBV is able to reroute the TNF receptor family signaling pathway (Izumi and Kieff, 1997; Le Cloennec et al., 2008; Liebowitz, 1998; Mosialos et al., 1995).

Such interactions favor EBV persistence, yet EBV latency may also provide mutualistic benefit to its hosts as an immune

adjuvant (White et al., 2010), protecting against lethal *Listeria monocytogenes* and *Yersinia pestis* infections (Barton et al., 2007). Over a host’s lifetime, incompletely characterized stimuli occasionally induce EBV to emerge from latency and initiate a lytic state via sequential expression of genes responsible for replication and whole virion assembly. This (generally clinically silent) replication results in viral shedding and potential spread to other EBV-naïve hosts.

EBV-Associated Cancer as a Consequence of Persistence

EBV plays a part in neoplastic transformation when latency is breached. EBV LMP1 and LMP2A can activate the mTOR, AKT, and PI3K pathways regulating functions relevant to tumorigenesis, including cellular proliferation, growth, survival, and mobility (Fukuda and Longnecker, 2007; Moody et al., 2005; Swart et al., 2000), whereas LMP1 miRNA inhibits the tumor suppressor p53 (Fukuda and Longnecker, 2007; Liu et al., 2005; Moody et al., 2005; Swart et al., 2000). Signaling of tumor suppression pathways that initiate cell-cycle arrest and priming of apoptotic pathways occurs when latency is lost. EBV-associated neoplasms show three distinct patterns of latency-associated gene expression (Rowe et al., 1992). Burkitt’s lymphoma exemplifies the Latency I program in which the Qp promoter-induced EBNA1 is expressed with small EBV-encoded RNAs (EBERs) and BamHI-A rightward transcript (BART). Latency II, characteristic of nasopharyngeal carcinoma (NPC), EBV-positive Hodgkin’s lymphoma, EBV-positive gastric carcinoma, and

T and NK cell lymphomas, involves expression of EBERs, BART, and Qp promoter-induced EBNA, with added LMP1, 2A, and /or 2B expression (Brooks et al., 1992). PTLDs are associated with the Latency III program in which all EBV latent gene products are expressed. EBV Latency III-regulated gene products mediate cell migration, antigen presentation, MAP kinase pathway, and interferon (IFN) signaling (Cahir-McFarland et al., 2004).

Latency I Program: EBV-Associated Burkitt's Lymphoma, Exogenous Cofactors, and c-Myc

Burkitt's lymphoma, a high-grade B cell malignancy, has distinct clinical-epidemiological variants: endemic (eBL), sporadic (sBL), and HIV associated (HIVBL). Each of these tumors has reciprocal chromosomal translocations involving immunoglobulin loci on chromosomes 14, 22, or 2 and *c-myc* (*MYC*) on chromosome 8 (Manolov and Manolova, 1972; Dalla-Favera et al., 1982), but only eBL tumors incorporate EBV DNA. Typical of Latency I, only EBNA1 is expressed in eBL, which is the most common pediatric tumor in Sub-Saharan Africa, where EBV acquisition occurs very early in life. Its distribution in regions of Africa and Papua New Guinea, where malaria is holoendemic, has implicated *P. falciparum* as cofactor, promoting lymphoma through immunosuppressive effects on EBV-specific T cell immunity (Njie et al., 2009; Whittle et al., 1984) and B cell proliferation involving *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) interactions with host memory B cells harboring latent EBV (Chêne et al., 2007). An alternative mechanism implicates malaria and initial EBV-induced B cell proliferation, with consequent activation-induced deaminase (AID) dysregulation leading to the characteristic *c-myc* translocation and lymphoma (Thorley-Lawson and Duca, 2007). In that schema, emergence of sBL reflects spontaneous (non-microbe-driven) *c-myc* translocation, whereas in eBL an EBV-driven series of events abetted by *P. falciparum* culminates in the characteristic oncogenic *c-myc*.

Latency II Program: Host HLA Types and EBV-Associated Nasopharyngeal Carcinoma

EBV is present in epithelial NPC cells, where it establishes a latency pattern with EBNA1 and either LMP1 or LMP2 protein expression (Latency II) (Brooks et al., 1992). The highest incidence of NPC is in Southeast China, particularly in Guangxi Province, where it occurs in association with specific host HLA haplotypes (Tang et al., 2010). The underlying pathogenesis of EBV-induced NPC remains obscure.

Latency III Program: Host Immune Suppression and EBV-Associated PTLD

PTLDs represent heterogeneous diseases that vary from reactive polyclonal B cell hyperplasia to monoclonal tumors to fatal, aggressive non-Hodgkin's lymphomas (Penn et al., 1969). PTLT may occur after hematopoietic stem cell or solid organ transplantation. Most cases of PTLT are of B cell origin and EBV associated (Young et al., 1989). Intensive immunosuppressive regimens to avoid graft rejection affect risk for PTLT development. The highest incidence of PTLT after small bowel transplantation compared to other organs (e.g., kidney) may relate to the quantity of transplanted lymphoid tissue, with more EBV + B cell populations (Cohen, 2000). EBV latency becomes disrupted in PTLTs, diseases related to the intersection of 20th century medical technologies with an ancient virome constituent. PTLT lesions express EBV Latency III genes, whose encoded proteins are involved in signal transduction, transcription, and protein

catabolism and in cell motility, shape, and adhesion characteristics (Carter et al., 2002; Delecluse et al., 1995; McKnight et al., 1994; Rea et al., 1994). Impaired α -EBV T cell function permits EBV-driven B cell proliferation, resulting in PTLT.

Future Therapies

Hanahan and Weinberg outline ten therapeutic approaches to target the central functional and enabling pathways involved in cancer (Hanahan and Weinberg, 2011). We envision that microbes can be harnessed (Blaser, 1997, 2010) to perform many of these therapeutic functions. For example, colonization of specific niches in the gut lumen (stomach, distal esophagus, rectum) with probiotic bacterial strains capable of modulating local inflammation and immunity could help control luminal gastrointestinal tract neoplasia. Similarly, establishment and maintenance of an estrobolome (with diminished deconjugation activity) that favors estrogen excretion pathways may reduce risk of developing estrogen-driven malignancy. Knowledge of the microbiome can be applied to targeting both specific anatomic sites and functional capabilities. Members of the human microbiota can suppress aspects of cellular immunity (e.g., *B. fragilis* [Mazmanian et al., 2008; Round et al., 2011]), whereas others (e.g., *cagA*⁺ *H. pylori*) induce proinflammatory cytokines (Backert and Selbach, 2008). In the future, we can either beneficially target particular effector microbes to the desired location or engineer the desired genes into microbes that naturally colonize those sites.

Conclusions

The examples provided are not comprehensive, but rather indicate several conserved and paradigmatic mechanisms; microbiome constituents likely will have roles in other human cancers (Garrett et al., 2009; Wu et al., 2009). As recently discussed (Dominguez-Bello et al., 2011), nature must remove senescent individuals to liberate resources for younger members of the same species. A role for our ancient, interactive, residential microbes in clock-like functions (Blaser, 1997) is intuitive. In that manner, our residents may be true symbionts, improving host fitness early in life through metabolic and pathogen defense functions and leading to demise through neoplasia in the postreproductive period. If the hypothesis that malignancy is part of mammalian selection is correct, then other human cancers whose rates are log linear with age will predictably be found to reflect microbiome-induced pathogenesis.

Finally, the microbiome affects the metabolism of xenobiotics (Figure 2), such as pharmaceutical agents (Clayton et al., 2009), including those used to treat cancer. Responses to particular chemotherapeutic agents have been linked to specific gut microbiome metabolic activities (Wallace et al., 2010). Better knowledge of microbiome composition and metabolic activities will ultimately improve therapeutic choices, with new agents, dosing regimens, and monitoring strategies. Using such knowledge should improve therapeutic/toxic ratios and represents another exciting frontier in cancer research.

ACKNOWLEDGMENTS

This work was supported by R01GM63270, R01DK090989, UH2 AR057506, 5 P30 CA016087, and 1UL1RR029893 from the National Institutes of Health,

by the Diane Belfer Program for Human Microecology, and by the Margaret Q. Landenberger Foundation.

REFERENCES

- Adlercreutz, H. (1962). Studies on oestrogen excretion in human bile. *Acta Endocrinol. Suppl. (Copenh.)* 42 (Suppl 72), 1–220.
- Adlercreutz, H., and Järvenpää, P. (1982). Assay of estrogens in human feces. *J. Steroid Biochem.* 17, 639–645.
- Adlercreutz, H., and Martin, F. (1980). Biliary excretion and intestinal metabolism of progesterone and estrogens in man. *J. Steroid Biochem.* 13, 231–244.
- Adlercreutz, H., Martin, F., and Lindström, B. (1978). Gas chromatographic and mass spectrometric studies on oestrogens in bile—2. Men and non-pregnant women. *J. Steroid Biochem.* 9, 1197–1205.
- Adlercreutz, H., Martin, F., Järvenpää, P., and Fotsis, T. (1979). Steroid absorption and enterohepatic recycling. *Contraception* 20, 201–223.
- Ames, B.N., and Gold, L.S. (1990). Too many rodent carcinogens: mitogenesis increases mutagenesis. *Science* 249, 970–971.
- Andersson, A.F., Lindberg, M., Jakobsson, H., Bäckhed, F., Nyrén, P., and Engstrand, L. (2008). Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS ONE* 3, e2836.
- Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., Fernandes, G.R., Tap, J., Bruls, T., Batto, J.M., et al; MetaHIT Consortium. (2011). Enterotypes of the human gut microbiome. *Nature* 473, 174–180.
- Atherton, J.C., and Blaser, M.J. (2009). Coadaptation of *Helicobacter pylori* and humans: ancient history, modern implications. *J. Clin. Invest.* 119, 2475–2487.
- Babcock, G.J., Decker, L.L., Volk, M., and Thorley-Lawson, D.A. (1998). EBV persistence in memory B cells in vivo. *Immunity* 9, 395–404.
- Backert, S., and Selbach, M. (2008). Role of type IV secretion in *Helicobacter pylori* pathogenesis. *Cell. Microbiol.* 10, 1573–1581.
- Bardhan, P.K. (1997). Epidemiological features of *Helicobacter pylori* infection in developing countries. *Clin. Infect. Dis.* 25, 973–978.
- Barton, E.S., White, D.W., Cathelyn, J.S., Brett-McClellan, K.A., Engle, M., Diamond, M.S., Miller, V.L., and Virgin, H.W., 4th. (2007). Herpesvirus latency confers symbiotic protection from bacterial infection. *Nature* 447, 326–329.
- Batista, S.A., Rocha, G.A., Rocha, A.M., Saraiva, I.E., Cabral, M.M., Oliveira, R.C., and Queiroz, D.M. (2011). Higher number of *Helicobacter pylori* CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. *BMC Microbiol.* 11, 61.
- Benson, A.K., Kelly, S.A., Legge, R., Ma, F., Low, S.J., Kim, J., Zhang, M., Oh, P.L., Nehrenberg, D., Hua, K., et al. (2010). Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. *Proc. Natl. Acad. Sci. USA* 107, 18933–18938.
- Bik, E.M., Eckburg, P.B., Gill, S.R., Nelson, K.E., Purdom, E.A., Francois, F., Perez-Perez, G., Blaser, M.J., and Relman, D.A. (2006). Molecular analysis of the bacterial microbiota in the human stomach. *Proc. Natl. Acad. Sci. USA* 103, 732–737.
- Blaser, M.J. (1997). Ecology of *Helicobacter pylori* in the human stomach. *J. Clin. Invest.* 100, 759–762.
- Blaser, M.J. (2008). Understanding microbe-induced cancers. *Cancer Prev. Res. (Phila.)* 1, 15–20.
- Blaser, M.J. (2010). Harnessing the power of the human microbiome. *Proc. Natl. Acad. Sci. USA* 107, 6125–6126.
- Blaser, M.J., and Falkow, S. (2009). What are the consequences of the disappearing human microbiota? *Nat. Rev. Microbiol.* 7, 887–894.
- Blaser, M.J., and Kirschner, D. (2007). The equilibria that allow bacterial persistence in human hosts. *Nature* 449, 843–849.
- Bradlow, H.L., Davis, D.L., Lin, G., Sepkovic, D., and Tiwari, R. (1995). Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrogens: a biologic marker of breast cancer risk. *Environ. Health Perspect.* 103 (Suppl 7), 147–150.
- Brooks, L., Yao, Q.Y., Rickinson, A.B., and Young, L.S. (1992). Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. *J. Virol.* 66, 2689–2697.
- Cahir-McFarland, E.D., Carter, K., Rosenwald, A., Giltneane, J.M., Henrickson, S.E., Staudt, L.M., and Kieff, E. (2004). Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. *J. Virol.* 78, 4108–4119.
- Callan, M.F., Steven, N., Krausa, P., Wilson, J.D., Moss, P.A., Gillespie, G.M., Bell, J.I., Rickinson, A.B., and McMichael, A.J. (1996). Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. *Nat. Med.* 2, 906–911.
- Carter, K.L., Cahir-McFarland, E., and Kieff, E. (2002). Epstein-barr virus-induced changes in B-lymphocyte gene expression. *J. Virol.* 76, 10427–10436.
- Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., Muti, P., Rogan, E., Russo, J., Santen, R., and Sutter, T. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. *Biochim. Biophys. Acta* 1766, 63–78.
- Chen, Y., and Blaser, M.J. (2008). *Helicobacter pylori* colonization is inversely associated with childhood asthma. *J. Infect. Dis.* 198, 553–560.
- Chêne, A., Donati, D., Guerreiro-Cacais, A.O., Levitsky, V., Chen, Q., Falk, K.I., Orem, J., Kironde, F., Wahlgren, M., and Bejarano, M.T. (2007). A molecular link between malaria and Epstein-Barr virus reactivation. *PLoS Pathog.* 3, e80.
- Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R., and Nicholson, J.K. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. *Proc. Natl. Acad. Sci. USA* 106, 14728–14733.
- Cohen, J.I. (2000). Epstein-Barr virus infection. *N. Engl. J. Med.* 343, 481–492.
- Cole, C.B., Fuller, R., Mallet, A.K., and Rowland, I.R. (1985). The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds. *J. Appl. Bacteriol.* 59, 549–553.
- Dabek, M., McCrae, S.I., Stevens, V.J., Duncan, S.H., and Louis, P. (2008). Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. *FEMS Microbiol. Ecol.* 66, 487–495.
- Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., and Croce, C.M. (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc. Natl. Acad. Sci. USA* 79, 7824–7827.
- Delecluse, H.J., Kremmer, E., Rouault, J.P., Cour, C., Bornkamm, G., and Berger, F. (1995). The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. *Am. J. Pathol.* 146, 1113–1120.
- Dethlefsen, L., McFall-Ngai, M., and Relman, D.A. (2007). An ecological and evolutionary perspective on human-microbe mutualism and disease. *Nature* 449, 811–818.
- Devesa, S.S., Blot, W.J., and Fraumeni, J.F., Jr. (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer* 83, 2049–2053.
- Dominguez-Bello, M.G., Blaser, M.J., Ley, R.E., and Knight, R. (2011). Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. *Gastroenterology* 140, 1713–1719.
- El-Omar, E.M., Carrington, M., Chow, W.H., McColl, K.E., Bream, J.H., Young, H.A., Herrera, J., Lissowska, J., Yuan, C.C., Rothman, N., et al. (2001). The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. *Nature* 412, 99.
- El-Omar, E.M., Rabkin, C.S., Gammon, M.D., Vaughan, T.L., Risch, H.A., Schoenberg, J.B., Stanford, J.L., Mayne, S.T., Goedert, J., Blot, W.J., et al. (2003). Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 124, 1193–1201.
- Eriksson, H. (1970). Steroids in germfree and conventional rats. Unconjugated metabolites of [4-14C]pregnenolone and [4-14C]corticosterone in faeces from female rats. *Eur. J. Biochem.* 16, 261–267.

- Faith, J.J., McNulty, N.P., Rey, F.E., and Gordon, J.I. (2011). Predicting a human gut microbiota's response to diet in gnotobiotic mice. *Science* 333, 101–104.
- Figueiredo, C., Machado, J.C., Pharoah, P., Seruca, R., Sousa, S., Carvalho, R., Capelinha, A.F., Quint, W., Caldas, C., van Doorn, L.J., et al. (2002). Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J. Natl. Cancer Inst.* 94, 1680–1687.
- Francois, F., Roper, J., Goodman, A.J., Pei, Z., Ghumman, M., Mourad, M., de Perez, A.Z., Perez-Perez, G.I., Tseng, C.H., and Blaser, M.J. (2008). The association of gastric leptin with oesophageal inflammation and metaplasia. *Gut* 57, 16–24.
- Francois, F., Roper, J., Joseph, N., Pei, Z., Chhada, A., Shak, J.R., de Perez, A.Z., Perez-Perez, G.I., and Blaser, M.J. (2011). The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. *BMC Gastroenterol.* 11, 37.
- Fukuda, M., and Longnecker, R. (2007). Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. *J. Virol.* 81, 9299–9306.
- Gaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009). The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. *Immunity* 31, 677–689.
- Gadelle, D., Raibaud, P., and Sacquet, E. (1985). beta-Glucuronidase activities of intestinal bacteria determined both in vitro and in vivo in gnotobiotic rats. *Appl. Environ. Microbiol.* 49, 682–685.
- Garrett, W.S., Punit, S., Gallini, C.A., Michaud, M., Zhang, D., Sigrist, K.S., Lord, G.M., Glickman, J.N., and Glimcher, L.H. (2009). Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. *Cancer Cell* 16, 208–219.
- Gaudreault, E., Fiola, S., Olivier, M., and Gosselin, J. (2007). Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. *J. Virol.* 81, 8016–8024.
- Gloux, K., Berteau, O., El Oumami, H., Béguet, F., Leclerc, M., and Doré, J. (2011). A metagenomic β -glucuronidase uncovers a core adaptive function of the human intestinal microbiome. *Proc. Natl. Acad. Sci. USA* 108 (Suppl 1), 4539–4546.
- Goldin, B.R., Adlercreutz, H., Gorbach, S.L., Warram, J.H., Dwyer, J.T., Swenson, L., and Woods, M.N. (1982). Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. *N. Engl. J. Med.* 307, 1542–1547.
- Gorbach, S.L., and Goldin, B.R. (1987). Diet and the excretion and enterohepatic cycling of estrogens. *Prev. Med.* 16, 525–531.
- Gupta, M., McDougal, A., and Safe, S. (1998). Estrogenic and antiestrogenic activities of 16 α - and 2-hydroxy metabolites of 17 β -estradiol in MCF-7 and T47D human breast cancer cells. *J. Steroid Biochem. Mol. Biol.* 67, 413–419.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- Hankinson, S.E., Willett, W.C., Manson, J.E., Colditz, G.A., Hunter, D.J., Spiegelman, D., Barbieri, R.L., and Speizer, F.E. (1998). Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J. Natl. Cancer Inst.* 90, 1292–1299.
- Henle, G., Henle, W., Clifford, P., Diehl, V., Kafuko, G.W., Kirya, B.G., Klein, G., Morrow, R.H., Munube, G.M., Pike, P., et al. (1969). Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. *J. Natl. Cancer Inst.* 43, 1147–1157.
- Houghton, J., Stoicov, C., Nomura, S., Rogers, A.B., Carlson, J., Li, H., Cai, X., Fox, J.G., Goldenring, J.R., and Wang, T.C. (2004). Gastric cancer originating from bone marrow-derived cells. *Science* 306, 1568–1571.
- Islami, F., and Kamangar, F. (2008). Helicobacter pylori and esophageal cancer risk: a meta-analysis. *Cancer Prev. Res. (Phila.)* 1, 329–338.
- Israel, D.A., Salama, N., Arnold, C.N., Moss, S.F., Ando, T., Wirth, H.P., Tham, K.T., Camorlinga, M., Blaser, M.J., Falkow, S., and Peek, R.M., Jr. (2001). Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. *J. Clin. Invest.* 107, 611–620.
- Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K.C., Santee, C.A., Lynch, S.V., et al. (2009). Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 139, 485–498.
- Izumi, K.M., and Kieff, E.D. (1997). The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF- κ B. *Proc. Natl. Acad. Sci. USA* 94, 12592–12597.
- Järvenpää, P., Kosunen, T., Fotsis, T., and Adlercreutz, H. (1980). In vitro metabolism of estrogens by isolated intestinal micro-organisms and by human faecal microflora. *J. Steroid Biochem.* 13, 345–349.
- Jeyakumar, M., Carlson, K.E., Gunther, J.R., and Katzenellenbogen, J.A. (2011). Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. *J. Biol. Chem.* 286, 12971–12982.
- Kaaks, R., Berrino, F., Key, T., Rinaldi, S., Dossus, L., Biessy, C., Secretò, G., Amiano, P., Bingham, S., Boeing, H., et al. (2005). Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). *J. Natl. Cancer Inst.* 97, 755–765.
- Kabat, G.C., Chang, C.J., Sparano, J.A., Sepkovic, D.W., Hu, X.P., Khalil, A., Rosenblatt, R., and Bradlow, H.L. (1997). Urinary estrogen metabolites and breast cancer: a case-control study. *Cancer Epidemiol. Biomarkers Prev.* 6, 505–509.
- Karnes, W.E., Jr., Samloff, I.M., Siurala, M., Kekki, M., Sipponen, P., Kim, S.W., and Walsh, J.H. (1991). Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. *Gastroenterology* 101, 167–174.
- Key, T., Appleby, P., Barnes, I., and Reeves, G.; Endogenous Hormones and Breast Cancer Collaborative Group. (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J. Natl. Cancer Inst.* 94, 606–616.
- Kuiper, G.G., Enmark, E., Peltö-Huikko, M., Nilsson, S., and Gustafsson, J.A. (1996). Cloning of a novel receptor expressed in rat prostate and ovary. *Proc. Natl. Acad. Sci. USA* 93, 5925–5930.
- Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., and Gustafsson, J.A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 139, 4252–4263.
- Kung, C.P., and Raab-Traub, N. (2010). Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- κ B pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. *J. Virol.* 84, 6605–6614.
- Lacoste, V., Lavergne, A., de Thoisy, B., Pouliquen, J.F., and Gessain, A. (2010). Genetic diversity and molecular evolution of human and non-human primate Gammaherpesvirinae. *Infect. Genet. Evol.* 10, 1–13.
- Lakhani, N.J., Sarkar, M.A., Venitz, J., and Figg, W.D. (2003). 2-Methoxyestradiol, a promising anticancer agent. *Pharmacotherapy* 23, 165–172.
- Le Cloennec, C., Ouk, T.S., Youlyouy-Marfak, I., Panteix, S., Martin, C.C., Rastelli, J., Adriaenssens, E., Zimmer-Strobl, U., Coll, J., Feuillard, J., and Jayat-Vignoles, C. (2008). Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis. *J. Virol.* 82, 6721–6733.
- Lederberg, J., and McCray, A.T. (2001). 'Ome sweet 'omics—A genealogical treasury of words. *Scientist* 17, 8.
- Lee, I.O., Kim, J.H., Choi, Y.J., Pillinger, M.H., Kim, S.Y., Blaser, M.J., and Lee, Y.C. (2010). Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. *J. Biol. Chem.* 285, 16042–16050.
- Ley, R.E., Peterson, D.A., and Gordon, J.I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 124, 837–848.
- Ley, R.E., Hamady, M., Lozupone, C., Turnbaugh, P.J., Ramey, R.R., Bircher, J.S., Schlegel, M.L., Tucker, T.A., Schrenzel, M.D., Knight, R., and Gordon, J.I. (2008a). Evolution of mammals and their gut microbes. *Science* 320, 1647–1651.

- Ley, R.E., Lozupone, C.A., Hamady, M., Knight, R., and Gordon, J.I. (2008b). Worlds within worlds: evolution of the vertebrate gut microbiota. *Nat. Rev. Microbiol.* 6, 776–788.
- Li, M., Wang, B., Zhang, M., Rantalainen, M., Wang, S., Zhou, H., Zhang, Y., Shen, J., Pang, X., Zhang, M., et al. (2008). Symbiotic gut microbes modulate human metabolic phenotypes. *Proc. Natl. Acad. Sci. USA* 105, 2117–2122.
- Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., and Hemminki, K. (2000). Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N. Engl. J. Med.* 343, 78–85.
- Liebowitz, D. (1998). Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. *N. Engl. J. Med.* 338, 1413–1421.
- Linz, B., Balloux, F., Moodley, Y., Manica, A., Liu, H., Roumagnac, P., Falush, D., Stamer, C., Prugnolle, F., van der Merwe, S.W., et al. (2007). An African origin for the intimate association between humans and *Helicobacter pylori*. *Nature* 445, 915–918.
- Liu, M.T., Chang, Y.T., Chen, S.C., Chuang, Y.C., Chen, Y.R., Lin, C.S., and Chen, J.Y. (2005). Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. *Oncogene* 24, 2635–2646.
- Lombardi, P., Goldin, B., Boutin, E., and Gorbach, S.L. (1978). Metabolism of androgens and estrogens by human fecal microorganisms. *J. Steroid Biochem.* 9, 795–801.
- Lukanova, A., Lundin, E., Micheli, A., Arslan, A., Ferrari, P., Rinaldi, S., Krogh, V., Lenner, P., Shore, R.E., Biessy, C., et al. (2004). Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. *Int. J. Cancer* 108, 425–432.
- Maldonado-Contreras, A., Goldfarb, K.C., Godoy-Vitorino, F., Karaoz, U., Contreras, M., Blaser, M.J., Brodie, E.L., and Dominguez-Bello, M.G. (2011). Structure of the human gastric bacterial community in relation to *Helicobacter pylori* status. *ISME J.* 5, 574–579.
- Manolov, G., and Manolova, Y. (1972). Marker band in one chromosome 14 from Burkitt lymphomas. *Nature* 237, 33–34.
- Martin, F., Peltonen, J., Laatikainen, T., Pulkkinen, M., and Adlercreutz, H. (1975). Excretion of progesterone metabolites and estriol in faeces from pregnant women during ampicillin administration. *J. Steroid Biochem.* 6, 1339–1346.
- Mazmanian, S.K., Round, J.L., and Kasper, D.L. (2008). A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* 453, 620–625.
- McBain, A.J., and Macfarlane, G.T. (1998). Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites. *J. Med. Microbiol.* 47, 407–416.
- McGeoch, D.J., Cook, S., Dolan, A., Jamieson, F.E., and Telford, E.A. (1995). Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. *J. Mol. Biol.* 247, 443–458.
- McKnight, J.L., Cen, H., Riddler, S.A., Breinig, M.C., Williams, P.A., Ho, M., and Joseph, P.S. (1994). EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. *Leuk. Lymphoma* 15, 9–16.
- Meilahn, E.N., De Stavola, B., Allen, D.S., Fentiman, I., Bradlow, H.L., Sepkovic, D.W., and Kuller, L.H. (1998). Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. *Br. J. Cancer* 78, 1250–1255.
- Miyashita, E.M., Yang, B., Lam, K.M., Crawford, D.H., and Thorley-Lawson, D.A. (1995). A novel form of Epstein-Barr virus latency in normal B cells in vivo. *Cell* 80, 593–601.
- Moody, C.A., Scott, R.S., Amirghahari, N., Nathan, C.O., Young, L.S., Dawson, C.W., and Sixbey, J.W. (2005). Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. *J. Virol.* 79, 5499–5506.
- Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E. (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. *Cell* 80, 389–399.
- Moss, S.F., Legon, S., Bishop, A.E., Polak, J.M., and Calam, J. (1992). Effect of *Helicobacter pylori* on gastric somatostatin in duodenal ulcer disease. *Lancet* 340, 930–932.
- Muegge, B.D., Kuczynski, J., Knights, D., Clemente, J.C., González, A., Fontana, L., Henrissat, B., Knight, R., and Gordon, J.I. (2011). Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. *Science* 332, 970–974.
- Muti, P., Bradlow, H.L., Micheli, A., Krogh, V., Freudenheim, J.L., Schüenemann, H.J., Stanulla, M., Yang, J., Sepkovic, D.W., Trevisan, M., and Berrino, F. (2000). Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16 α -hydroxyestrone ratio in premenopausal and postmenopausal women. *Epidemiology* 11, 635–640.
- Niedermaier, J.C., Evans, A.S., Subrahmanyam, L., and McCollum, R.W. (1970). Prevalence, incidence and persistence of EB virus antibody in young adults. *N. Engl. J. Med.* 282, 361–365.
- Njie, R., Bell, A.I., Jia, H., Croom-Carter, D., Chaganti, S., Hislop, A.D., Whittle, H., and Rickinson, A.B. (2009). The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. *J. Infect. Dis.* 199, 31–38.
- Nordling, C.O. (1953). A new theory on cancer-inducing mechanism. *Br. J. Cancer* 7, 68–72.
- Odenbreit, S., Püls, J., Sedlmaier, B., Gerland, E., Fischer, W., and Haas, R. (2000). Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* 287, 1497–1500.
- Parsonnet, J., Hansen, S., Rodriguez, L., Gelb, A.B., Warnke, R.A., Jellum, E., Orentreich, N., Vogelman, J.H., and Friedman, G.D. (1994). *Helicobacter pylori* infection and gastric lymphoma. *N. Engl. J. Med.* 330, 1267–1271.
- Peek, R.M., Jr., and Blaser, M.J. (2002). *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat. Rev. Cancer* 2, 28–37.
- Pei, Z., Bini, E.J., Yang, L., Zhou, M., Francois, F., and Blaser, M.J. (2004). Bacterial biota in the human distal esophagus. *Proc. Natl. Acad. Sci. USA* 101, 4250–4255.
- Penkert, R.R., and Kalejta, R.F. (2011). Tegument protein control of latent herpesvirus establishment and animation. *Herpesviridae* 2, 3.
- Penn, I., Hammond, W., Brettschneider, L., and Starzl, T.E. (1969). Malignant lymphomas in transplantation patients. *Transplant. Proc.* 1, 106–112.
- Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., et al; MetaHIT Consortium. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464, 59–65.
- Raftogianis, R., Creveling, C., Weinshilboum, R., and Weisz, J. (2000). Estrogen metabolism by conjugation. *J. Natl. Cancer Inst. Monogr.*, 113–124.
- Rea, D., Fourcade, C., Leblond, V., Rowe, M., Joab, I., Edelman, L., Bitker, M.O., Gandjbakhch, I., Suberbielle, C., Farcet, J.P., et al. (1994). Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. *Transplantation* 58, 317–324.
- Reyes, A., Haynes, M., Hanson, N., Angly, F.E., Heath, A.C., Rohwer, F., and Gordon, J.I. (2010). Viruses in the faecal microbiota of monozygotic twins and their mothers. *Nature* 466, 334–338.
- Robinson, K., Kenefick, R., Pidgeon, E.L., Shakib, S., Patel, S., Polson, R.J., Zaitoun, A.M., and Atherton, J.C. (2008). *Helicobacter pylori*-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. *Gut* 57, 1375–1385.
- Roosendaal, R., Kuipers, E.J., Buitenwerf, J., van Uffelen, C., Meuwissen, S.G., van Kamp, G.J., and Vandembroucke-Grauls, C.M. (1997). *Helicobacter pylori* and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. *Am. J. Gastroenterol.* 92, 1480–1482.
- Round, J.L., Lee, S.M., Li, J., Tran, G., Jabri, B., Chatila, T.A., and Mazmanian, S.K. (2011). The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science* 332, 974–977.
- Rowe, M., Lear, A.L., Croom-Carter, D., Davies, A.H., and Rickinson, A.B. (1992). Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. *J. Virol.* 66, 122–131.

- Sandberg, A.A., and Slaunwhite, W.R., Jr. (1957). Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women. *J. Clin. Invest.* **36**, 1266–1278.
- Schottenfeld, D., and Fraumeni, J.F. (2006). *Cancer epidemiology and prevention, Third Edition* (New York: Oxford University Press).
- Shimizu, K., Muranaka, Y., Fujimura, R., Ishida, H., Tazume, S., and Shimamura, T. (1998). Normalization of reproductive function in germfree mice following bacterial contamination. *Exp. Anim.* **47**, 151–158.
- Song, Y.J., and Kang, M.S. (2010). Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation. *Virus Genes* **41**, 174–180.
- Swart, R., Ruf, I.K., Sample, J., and Longnecker, R. (2000). Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. *J. Virol.* **74**, 10838–10845.
- Tang, M., Zeng, Y., Poisson, A., Marti, D., Guan, L., Zheng, Y., Deng, H., Liao, J., Guo, X., Sun, S., et al. (2010). Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. *Genes Immun.* **11**, 334–342.
- Tempera, I., Klichinsky, M., and Lieberman, P.M. (2011). EBV latency types adopt alternative chromatin conformations. *PLoS Pathog.* **7**, e1002180.
- Thiede, C., Wündisch, T., Alpen, B., Neubauer, B., Morgner, A., Schmitz, M., Ehninger, G., Stolte, M., Bayerdörffer, E., and Neubauer, A.; German MALT Lymphoma Study Group. (2001). Long-term persistence of monoclonal B cells after cure of *Helicobacter pylori* infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. *J. Clin. Oncol.* **19**, 1600–1609.
- Thorley-Lawson, D.A., and Duca, K.A. (2007). Pathogens cooperate in lymphomagenesis. *Nat. Med.* **13**, 906–907.
- Toniolo, P.G., Levitz, M., Zeleniuch-Jacquotte, A., Banerjee, S., Koenig, K.L., Shore, R.E., Strax, P., and Pasternack, B.S. (1995). A prospective study of endogenous estrogens and breast cancer in postmenopausal women. *J. Natl. Cancer Inst.* **87**, 190–197.
- Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R., and Gordon, J.I. (2007). The human microbiome project. *Nature* **449**, 804–810.
- Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., and Gordon, J.I. (2009). The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci. Transl. Med.* **1**, ra14.
- Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Srinivasan, S., Sitaraman, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T. (2010). Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* **328**, 228–231.
- Wallace, B.D., Wang, H., Lane, K.T., Scott, J.E., Orans, J., Koo, J.S., Venkatesh, M., Jobin, C., Yeh, L.A., Mani, S., and Redinbo, M.R. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science* **330**, 831–835.
- White, D.W., Keppel, C.R., Schneider, S.E., Reese, T.A., Coder, J., Payton, J.E., Ley, T.J., Virgin, H.W., and Fehniger, T.A. (2010). Latent herpesvirus infection arms NK cells. *Blood* **115**, 4377–4383.
- Whittle, H.C., Brown, J., Marsh, K., Greenwood, B.M., Seidelin, P., Tighe, H., and Wedderburn, L. (1984). T-cell control of Epstein-Barr virus-infected B cells is lost during *P. falciparum* malaria. *Nature* **312**, 449–450.
- Woolcott, C.G., Shvetsov, Y.B., Stanczyk, F.Z., Wilkens, L.R., White, K.K., Caberto, C., Henderson, B.E., Le Marchand, L., Kolonel, L.N., and Goodman, M.T. (2010). Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. *Endocr. Relat. Cancer* **17**, 125–134.
- Wotherspoon, A.C., Dogliani, C., Diss, T.C., Pan, L., Moschini, A., de Boni, M., and Isaacson, P.G. (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of *Helicobacter pylori*. *Lancet* **342**, 575–577.
- Wu, S., Rhee, K.J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.R., Huso, D.L., Brancati, F.L., Wick, E., McAllister, F., et al. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat. Med.* **15**, 1016–1022.
- Wynder, E.L., and Gori, G.B. (1977). Contribution of the environment to cancer incidence: an epidemiologic exercise. *J. Natl. Cancer Inst.* **58**, 825–832.
- Yager, E.J., Szaba, F.M., Kummer, L.W., Lanzer, K.G., Burkum, C.E., Smiley, S.T., and Blackman, M.A. (2009). gamma-Herpesvirus-induced protection against bacterial infection is transient. *Viral Immunol.* **22**, 67–72.
- Yamamoto, H., Nakamura, T., Matsuo, K., Tajika, M., Kawai, H., Ohmiya, N., Niwa, Y., Goto, H., and Nakamura, S. (2008). Significance of CXCR3 expression in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type for predicting responsiveness to *Helicobacter pylori* eradication. *Cancer Sci.* **99**, 1769–1773.
- Yang, L., Lu, X., Nossa, C.W., Francois, F., Peek, R.M., and Pei, Z. (2009). Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. *Gastroenterology* **137**, 588–597.
- Young, L., Alfieri, C., Hennessy, K., Evans, H., O'Hara, C., Anderson, K.C., Ritz, J., Shapiro, R.S., Rickinson, A., Kieff, E., et al. (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. *N. Engl. J. Med.* **321**, 1080–1085.
- Ziegler, R.G., Faupel-Badger, J.M., Sue, L.Y., Fuhrman, B.J., Falk, R.T., Boyd-Morin, J., Henderson, M.K., Hoover, R.N., Veenstra, T.D., Keefer, L.K., and Xu, X. (2010). A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. *J. Steroid Biochem. Mol. Biol.* **121**, 538–545.
- Zullo, A., Hassan, C., Cristofari, F., Andriani, A., De Francesco, V., Ierardi, E., Tomao, S., Stolte, M., Morini, S., and Vaira, D. (2010). Effects of *Helicobacter pylori* eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. *Clin. Gastroenterol. Hepatol.* **8**, 105–110.